Clinical Trials
8
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)β’ Click on a phase to view related trials
SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers
- Conditions
- Estrogen-receptor-low Breast CancerMetastatic Breast CancerTriple Negative Breast Cancer
- Interventions
- Drug: SOC Chemotherapy
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2025-10-14
- Lead Sponsor
- Kathy Miller
- Target Recruit Count
- 168
- Registration Number
- NCT05846789
- Locations
- πΊπΈ
Emory University, Atlanta, Georgia, United States
πΊπΈIU Health Joe and Shelly Schwarz Cancer Center, Carmel, Indiana, United States
πΊπΈIndiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States
Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer
- Conditions
- Metastatic Breast CancerHormone Receptor Positive TumorTriple Negative Breast Cancer
- Interventions
- First Posted Date
- 2019-10-22
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- Kathy Miller
- Target Recruit Count
- 34
- Registration Number
- NCT04134884
- Locations
- πΊπΈ
Indiana University Melvin & Bren Simon Cancer Center, Indianapolis, Indiana, United States
πΊπΈWake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer
- Conditions
- Triple Negative Breast CancerMetastatic Breast Cancer
- Interventions
- First Posted Date
- 2017-08-09
- Last Posted Date
- 2021-01-07
- Lead Sponsor
- Kathy Miller
- Target Recruit Count
- 18
- Registration Number
- NCT03243331
- Locations
- πΊπΈ
IU Simon Cancer Center, Indianapolis, Indiana, United States
Inhibiting Fatty Acid Synthase to Improve Efficacy of Neoadjuvant Chemotherapy
- First Posted Date
- 2015-11-03
- Last Posted Date
- 2021-12-15
- Lead Sponsor
- Kathy Miller
- Target Recruit Count
- 42
- Registration Number
- NCT02595372
- Locations
- πΊπΈ
Georgetown University, Washington, District of Columbia, United States
πΊπΈWashington Hospital, Washington, District of Columbia, United States
πΊπΈIndiana University Health North Hospital, Carmel, Indiana, United States
MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma
- Conditions
- Hepatocellular CarcinomaLiver CancerHCC
- Interventions
- First Posted Date
- 2015-10-14
- Last Posted Date
- 2022-07-26
- Lead Sponsor
- Kathy Miller
- Target Recruit Count
- 11
- Registration Number
- NCT02575339
- Locations
- πΊπΈ
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
πΊπΈUniversity of Illinois Cancer Center, Chicago, Illinois, United States
πΊπΈIndiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
- Prev
- 1
- 2
- Next